Neurology
🇺🇸 FDA Page 2FDA news and analysis for pharmaceutical BD, investment, and market access · 12 articles on this page
Gain critical insights into global neurology drug development, clinical trials, regulatory approvals, and market trends. Inform your pharma strategy.
Showing 13–24 of 59 articles
Axsome FDA Approval for Alzheimer's Agitation Drug
Rhythm Pharmaceuticals' IMCIVREE Receives European Commission Approval for Acquired Hypothalamic Obesity
ZETA SURGICAL Receives FDA 510(k) Clearance for Brain Surgery Navigation System
Axsome Therapeutics Receives FDA Approval for AUVELITY to Treat Alzheimer's Agitation - First-in-Class Breakthrough
AC Immune Advances ACI-24 Alzheimer's Trial to Final Cohort, Initiates ACI-19764 Phase 1 Study
Addex Advances Dipraglurant for Brain Injury Recovery, Reports 2025 Financial Results
AC Immune Initiates Final Cohort in Phase 1b/2 ABATE Trial for Anti-Abeta Alzheimer's Treatment
Alzheimer's Clinical Trial Failures: Insights from Semaglutide & Posdinemab FDA Trials
Purespring Therapeutics Publishes Study on NPHS2 Genetic Variants Driving Adult-Onset FSGS in US and UK Populations
Neurocrine Biosciences INGREZZA Shows Clinically Meaningful Improvement in Tardive Dyskinesia Study
Addex Therapeutics GABAB PAM Shows Promise for IPF-Related Chronic Cough in Preclinical Study
FDA Places Clinical Hold on Newron's Evenamide Phase III Trial for Treatment-Resistant Schizophrenia